P:5/11 – Rifampicin  by unknown
94 Abstracts
Methods: Eight P. aeruginosa isolates were obtained from clinical samples.
PMNs were freshly isolated from healthy human blood. Respiratory burst
was assessed by measurement ofluminol-enhanced chemiluminescence, and
the bactericidal activity of the PMNs was monitored via the loss ofbaeterial
viability (counting of colony-forming units). The bacteria were pre-treated
with ciprofloxacin at 0.5, 1.0 and 5.0 times MIC.
Results: The pre-treatment had no effect on bactericidal activity: nor on the
number of killed bacteria (5 x 102-2 x 103), neither on the time of action
(within I h, P > 0.1). After pre-treatment the respiratory burst started earlier
than in the untreated control (20 versus more than 90 min.). The respiratory
burst maximums are in between 1.5-7.0 mV and the response times are 10-
30 min.
Conclusions: The effects ofciprofloxacin on the bactericidal aL'tivity and the
respiratory burst differed and exhibited no clear connection with the
resistance (MIC) of isolates.
P:5/10 - Quinupristin/Dalfopristin
[WeP136] In vitro activity of qulnupristln/dalfopristin
(synercid) against gram-positive cocci Isolated from severe
infections in Poland
]. Krzyszton-Russjan. K. Nowak, W. Hryniewicz
Sera & Vaccines Central Research Laboratory, Warsaw, Poland
Objectives: To evaluate susceptibility to quinupristin/dalfopristin (Q-D) of
clinical isolates of major Gram-positive pathogens.
Methods: Two hundred and eighty-two clinical isolates of various Gram-
positive bacteria were used in the study. The collection consisted ofstrains of
Streptococcus pneumoniae (n = 40), S. pyogene.s (n = 10). Enterococcusfaecium
(n = 60), Staphylococcus aureus (MRSA, n = 40; MSSA, n = 60) and
coagulase-negative staphylococci. CNS (MRCNS, n = 42; MSCNS, n =
30). Susceptibility testing ofstreptococci was performed with E-tests, and of
staphylococci and enterococci - by disc-dilfusion method according to
NCClS. Strains observed as resistant to Q-D were additionally charac-
terised by MIC evaluation using E-tests and the agar dilution method in
accordance with the NCClS guidelines.
Results: All isolates of S. pneumoniae, S. pyogenes, and Staphylococcus spp.
were found susceptible to Q-D. Out of E. faecium strains two isolates
demonstrated resistance to this antibiotic. These isolates were characterised
by MIC values of4-8 Itg/m!. MICs ofQ-D for S. pneumoniae strains were
evaluated as 0.5-1.0 1Jg/ml, and for S. pyogenes strains - as 0.25-0.38Itg/m!.
Condusions: The study revealed a very high in vitro activity ofquinupristin/
dalfopristin against major Gram-positive pathogens. The antibiutic may be
very useful in treatment ofserious infections caused by multiresistant strains
(e.g. MRSA and vancomycin-resistant E.faecium).
IWeP137!ln vitro activities of quinupristin-dalfopristin.
Iinezolid. and new quinolones against over 1200 clinical isolates
of gram-positive bacteria in Taiwan
P. R. Hsueh!, L.]. Teng l ,].]. lu2,].]. WuJ , H.]. Pan l • Y. C. Chen!, S.
W. HOI, K. T. luh!
INational Taiwa" University; lTri-Service General Hospital; JNational
Cheng-Kung University Hospital, Taipei, Taiwan
Objectives: To determine the in vitro activities ofquinupristin-dalfopristin,
linezolid, and new quinolones for recent clinical isolates of gram-positive
bacteria.
Methods: A total of 1210 nonduplicate. clinical isolates of gram-positive
bacteria were recovered patients mainly treated at National Taiwan Uni-
versity Hospital (NTUH) from January 1996 to December 1999. These
isolates included 100 blood isolates of methicillin-resistant Staphylococcus
aureus, 461 ofcoagulasenegative staphylococci, 267 ofS. pneumoniae, 120 of
viridans streptococci, 150 ofVRE (vancomycin MICs of ~321Jg/ml).35 of
Leuconostocspp_spp., 8 ofPediococcus spp., and 69 ofLactobacillus spp. MICs of
these isolates for 12 antimicrobial agents were determined by using the
standard methods recommended by the National Committee for Clinical
Laboratory standards (NCelS).
Results: linezolid demonstrated the most potent activity (MIC90s, 2 1Jg/
ml) against all isolates tested. including MRSA. VRE, and vancomycin-
resistant bacteria. Quinupristin-dalfopristin showed limited activity against
vancvomycin-resistant E.faetium (MIC90, 16 pg/mL), Pediococcus (MIC90.
128 JIg/ml.), LeuconoSlOC (MIC90. 128 JIg/mL). and Lactobacillus spp.
(MIC90, 16 1Jg/ml). Moxifloxacin and trovafloxacin had good activity
against these isolates except for ciprofloxacin-resistant VRE and methicilIin-
resistant staphylococci.
Conduslons: Linezolid appears to be a promising antimicrobial agent for
the treatment of infections caused by gram-positive bacteria. Quinupristin-
dalfopristin is not a suitable alternative for managing infections due to
vancomycin-resistant E.faecium in Taiwan.
[WeP~ Antimicrobial combinations against MRSA .
S. Cassey. P. R. Chadwick
Salford Royal Hospitals NHS Trust, Salford, United Kingdom
Objective: To study the antibacterial effect of combinations of teicoplanin
en and quinupristin/dalfopristin (Q/D) with broad-spectrum antimicrobial
agents against MRSA (methicillin-resistant Staphylococcus aureus).
Methods: 10 diverse clinical isolates of MRSA were studied. MICs were
determined by Etest. Time-kill studies were performed using a broth
macrodilution method. Combinations oft and Q/D were studied with
ceftazidime, cefepime, piperaciIlin-tazobactam and meropcnem.
Results: T and Q/D alone had cidal and static activity respectively against
the isolates tested. Antagonism was demonstrated between T and Q/D for9{
10 isolates. Synergic or antagonistic effects were not generally seen with
combinations ofeither T or Q/D and broad-spectrum antimicrobial agents.
Conclusions: This srudy did not suggest any potential benefit or contra-
indication to the concurrent use of selected broad-spectrum antimicrobials
duting treatment ofMRSA infection with either T or Q/D. A potential for
antagonism between T and Q/D was demonstrated.
P:5/11 - Rifampicin
[WeP13SI Relationship between rpoB mutations in
Staphylococcus aureus and antimicrobial activities of rifampicin
and KRM-1648
T. A. Wichelhaus. V. Schafer, V. Brade. B. Boddinghaus
Institute ofMedical Microbiology, Frankfurt am Main, Germany
Objectives: This study was aimed at determining the in vitro antibacterial
activities of the rifamycin derivatives rifampicin and KRM-I648 against
Staphylococcus aureus and at correlating the level of resistance to both
rifamycins with the genetic alterations in the rpoB gene.
Methods: The in vitro antibacterial activities were determined against 150
Seaphylocouus aurt:'us isolates, induding 50 rifampicin_sensitive (R..ir) methi_
cillin-sensitive Staphylococcus aureus (MSSA), 50 Rif methicillin-resistant
Staphylococcus aureus (MRSA), and 50 rifampicin-resistant (Rif') MRSA.
Concerning RiF MRSA, the genetie alterations in the rpoB gene were
determined by PCR amplification and sequencing.
Results: The MICs of rifampicin and KRM-I648 for 90% ofRif Staphy-
lococ",s aureus isolates tested were 0.016 and 0.001 1Jg/ml, respectively.
Missense mutations within a 204 bp fragment covering clusters I and II of
the rifampicin resistance region could be demonstrated in all Rif" MRSA
isolates. The in vitro susceptibility testing of rifampicin and KRM-I648
against RiF MRSA isolates revealed different activities of the rifamycins
with respeL't to specific mutations within rpoB. Specific mutation sites could
be identified which exhibited high-level cross-resistance to both rifamycins.
while a subset of mutations were associated with an up to 100 fold better
activity ofKRM-l648.
Conclusions: The results provide evidence that the new rifamycin KRM-
1648 is a potent antimicrobial that displays a high activity even against a
subset of rifampicin-resistant Staphylococcus aureus isolates.
IWeP139[ Rapid detection of rifampidn resistance in
Mycobacterium tuberculosis clinical isolates using
mycobacteriophages
N. Galii,]. A. Dominguez, S. Blanco,]. lonca,]. M. Manterola, V.
Ausina
Servei de Microbiologia, Hospital Universitari Germans Trias i Pujol,
BaJalona, Spain
Objectives: To standardise a rapid, non-laborious and low-cost assay to
srudy the susceptibility of M. tulm-CIIlosis (MTB) clinieal ioolates to rif.lmpi-
cin by using myeobaeteriophage 029.
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Methods: The assay is based on the ability of viable mycobacteria to be
infected by lyric phage D29 after an overnight exposure to rifampicin. Any
phage outside the bacilli are chemically inactivated by ferrous ammonium
sulphate, while those inside are protected and replicate within the cells,
causing their lysis and the release of a new phage progeny. The phages are
detected by the formation of plaques in a lawn of the fast-grower M.
smegmatis after a 24 h incubation at 37°C. Results are available with a total
turnaround time of 48 h. The phage assay was evaluated testing 19 MTB
clinical isolates: 5 rifampicin-resistant isolates (also resistant to isoniazid) and
14 rifampicin-sensitive strains (l resistant to isoniazid and streptomycin,S
resistant to isoniazid and 8 sensitive strains). The results were compared to
the BACTEC 12B susceptibility testing method.
Results: The phage assay presented a reliable agreement level in comparison
to BACTEC 12B technique. Only one discordant result was found: 1 isolate
resistant to rifampicin and isoniazid according to BACTEC 12B was found
susceptible by the phage method. This discrepant result was confirmed after
repeated testing by the phage methodology.
Conclusions: A high correlation has been found between the phage techni-
que and the gold standard method. This simple low-cost methodology is
suitable for microbiology laboratories with limited resources, such as those
in developing COWltries.
IWeP140ISynergy between Colimicin (C) and Rifampin (R)
and between Meropenem (M) and Trovafloxacin (T) on
Adnetobacterbaumanii
E.]. Giamarellos-Bourboulis, P. Grecka, H. Giamarellou
4th Dept Internal Medicine, Athens Medical School, Athens, Greece
Objective: The incidence ofnosocomial infections by A. baumanii led to the
study of various interactions.
Methods: A 5 x 106 CFU{ml inoculum of 36 isolates resistant to 3rd
generation cephalosporins, amikacin, ciprofloxacin and R (MIC > 4I1g{ml)
and susceptible to C was over-time exposed to the interaction of 1x or 4 x
MIC of C and to 2 I1g{ml of R ie equal to its mean serum level. Thirteen
isolates susceptible to M and T were also exposed to the interaction ofM and
Tat 1 x MIC. Any ~210g 10 decrease achieved by the interaction compared
to the most active single agent was evaluated.
Results: Synergy was found as follows (% of isolates):
activity. MICSO were aroWld 4-8I1g{ml and MIC90 were over 8-161JS{ml.
Except for CampyloblUter sp and Yersinia sp.
Conclusion: Rifaximin is a non-absorbible antimicrobial agent, able to
reach concentrations higher than 200 I1g{ml. This is 10 times greater than
the MIC observed in the studied strains. Thus, rifaximin could be considered
as an altenative antibiotic to treat diarrhea while quinolones could be
reserved to treat other more important infections. However, this treatment
would not be an option for diarrhea caused by CampyloblUrer sp and Yersinia
sp.
P:5/12 - Antifungal agents
IWeP142! Microbiological aspects of candidosis rational
chemotherapy
A. YU. Maslov
Perm State Medical Acadany, Perm, Russian Federation
Objectives: Optimisation of antimycotic therapy.
Methods: Candida isolates were allocated from a clinical material: vaginal
secretion using the Saburo media (broth and agar). Identification of genus
and species was made using cultural attributes (type ofmycelium, formation
ofchlamidospores), assimilation tests and biochemical activity.
Level of resistance and minimal inhibitary concentrations (MIC) of
antimycotic preparations were determined in microvariant of a serial
dilutions method. The following preparations were used: amphotericin B,
natamycin, nistatine, levorine, flucytosine, c1otrimazole, myconazole, keto-
conazole, fluconazole.
Results: The investigated sample is highly geterogenic on presence of
resistance to antimycotic preparations and level of sensitivity to each of
preparations. The most effective preparations were ftucytosine and natarny-
cin (15 and 12% of resistant strains). Resistance to other antibiotics
(amphotericin B, nistatine, levorine) was marked rather seldom, but the
average parameters of MIC were higher (6.76; 55.16; 47.8 mcg{ml). The
resistance to thiazol derivatives was met authentically more often (more than
25% of resistant strains). The correlation analysis testified the pr~ce
incomplete cross resistance of fungi to these preparations.
Conclusions: The results ofantibiograms are a basis effective and eCOllOmic:
therapy of candidosis.
Conclusions: The interactions ofC and R at concentrations ofR achieved in
vivo but inactive in vitro and to a lesser extent of M ant T express a
considerable synergy promising for application in the therapy ofnosocomial
infections.
IWeP141 IIn vtlU activity of rifaximin against
enteropathogens producing traveler's diarrhoea
]. M. Sierra, M. Navia,]. Ruiz, M. Vargas,]. Gascon,]. Vila
Institut CIInic d'Infeccions i Immunologia, IDIBAPS, Hospital Clink,
Barcelona, Spain
Objectives: The main aim ofthis study was to evaluate the in vitro activity of
rifaximin against microorganisms causing diarrhoea to travelers from
different geographical areas, in comparison with other antimicrobial agents.
Methods: The MIC was done by the agar dilution method. Eight anti-
microbial agents (ampicillin, choramphenicol, trimetoprim, nalidixic acid,
ciprofloxacin, rifampicin and rifaximin (erythromicine was also used to
Campylobacter sp) were tested against 151 enteropathogens (28 E. coli
enteroagregative (EaggEC), 40 E. coli enterotoxigenic (ETEC), 20 Shigella
sonnei, 18 Shigella flexneri, 12 Salmonella sp, 12 Campylobacter sp, 11
Aeromonas sp, 10 Yersinia sp. MIC50MIC90 and percentage of resistance
were also calculated.
Results: Most of the antimicrobial agents presented a MIC90 ofaround 128
I-'g/ml or higher, thus showing high levels of resistance. Only quinolones
remain active. With the exception of Campylobacter sp, all the strains
presented low levels of resistance to nalidixic acid (EaggEC 3'5% and
Shigella sonnei 10%), and were susceptible to ciprofloxacin, MIC90 of 0.06
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IWeP143j Antifungal susceptibility testing using cytOmetric
methods
C. Pina-Vaz"', F. Sansonetty', A. Rodrigues', Sofia Costa-de-Oliveira',
A. Salvador2, A. F. Fonseca',]. Martinez-de-Oliveira3
I Dept. ofMicrobiology; 2IPA TIMUP-Illstitute ofPathology and Molecular
Immunology; 3Dept. ofGynecology, Porto School ofMedkine, University of
Porto, Portugal
Antifungal susceptibility testing remains dependent on the enumeration of
replication-competent yeast cells with long incubation times and semiquan-
titative and subjective endpoints.
Objectives: Determine the susceptibility ofCandida spp to the most impor-
tant antifungals using probes with specific cellular affinities.
Methods: Candida strains were tested according to NCCLS M27-A proto-
col for susceptibility testing to amphotericine B (AmB; Sigma), fluconazole
(Flu; Pfizer) and S-Flucitosine (S-FC; Sigma). Two sensitive and two
resistant strains were growns to stationary growth phase. 1<1' yeast cells/ml
were incubated with AmB 2 and 8l1g{ml; Flu 8 and 641JS{ml and S-FC 4 and
32.11g/ml, at 35°C with shaking for 1 hour; the cells were centrifuged and
stained, in separate vials, with propidium iodide (PI; Sigma) - Il1g/ml for 30
min, to measure membrane lesion, FUN-l (Molecular probes) - 0.5I1M{106
cells, to evaluate metabolic disturbance and JCl (Molecular probes) - 0.25
I1M{106 cells, a marker ofintegrity ofmitochondrial potential. The suspen-
sions were analyzed by flow cytometty (FCM) and epifluorescence micro-
scopy (EFM). Viability studies were done in parallel by counting the colony-
forming units (CFU).
Results: FUN-l staining evidentiated subletal yeast changes (increase in
intensity of fluorescence using FCM-FL2 and a decrease on cylindrical
intravacuolar strucrures by EFC) on sensitive strains to Flu and S-FC:
susceptibility to AmB could only be detect by JCt staining (decrease on
FL2{FLt by FCM or a decrease ofJC aggregates by EFM). PI was unable to
stain the cells after those treatments.
Conclusions: Assessment of the effect of different drugs can be quick and
reliably determined using different fluorescent probes.
